Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Updated results from CARTITUDE-1

Yi Lin • 11 Jun 2022
EHA 2022
Multiple Myeloma CAR-T Ciltacabtagene autoleucel
CARTITUDE-1

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some updated results from a 27-month follow-up of the CARTITUDE-1 trial (NCT03548207), investigating the use of ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory (R/R) myeloma, drawing focus on the impressive response rates observed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Yi Lin

1:59
Factors to consider when choosing between cilta-cel and ide-cel for R/R multiple myeloma
Yi Lin • 9 Dec 2023
1:50
Real-world outcomes of teclistamab treatment in R/R multiple myeloma
Yi Lin • 9 Dec 2023
1:32
AEs associated with CAR-T in patients with triple-class exposed R/R MM: analysis from KarMMa-3
Yi Lin • 9 Dec 2023
3:04
Outpatient monitoring following CAR-T and BsAb treatment for patients with lymphoma and MM
Yi Lin • 9 Dec 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals